Brensocatib is a promising investigational medication currently under evaluation for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) and other neutrophil-driven diseases, including conditions related to Aspergillus infections like aspergillosis. This article explores how brensocatib may benefit patients with aspergillosis, particularly those dealing with bronchiectasis and other complications that arise from chronic Aspergillus infections.
Note that brensocatib is NOT a cure for bronchiectasis or aspergillosis.
What is Brensocatib?
Brensocatib is an oral Dipeptidyl Peptidase 1 (DPP-1) inhibitor, a new class of drugs that targets neutrophil serine proteases, which are enzymes involved in the inflammation and tissue damage seen in chronic respiratory diseases. By inhibiting DPP-1, brensocatib reduces the activation of these destructive enzymes, leading to less inflammation and potentially slowing disease progression.
In clinical trials, brensocatib has shown significant promise in reducing the frequency of pulmonary exacerbations and slowing the decline in lung function for patients with bronchiectasis. This makes it an intriguing treatment option for individuals with Aspergillus-related diseases like chronic pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis (ABPA), and other forms of aspergillosis.
How Brensocatib May Benefit Aspergillosis Patients
1. Impact on Bronchiectasis in Aspergillosis
For many aspergillosis patients, bronchiectasis—a condition characterized by the permanent dilation of the bronchi—is a significant complication. In ABPA and CPA, Aspergillus infection contributes to chronic inflammation in the lungs, which can lead to bronchial damage and bronchiectasis. This increases the risk of frequent exacerbations and lung function decline.
Brensocatib works by reducing neutrophil-driven inflammation in the lungs, which could help prevent further lung damage and progression of bronchiectasis. By reducing inflammation and improving airway function, brensocatib may offer significant benefits for aspergillosis patients with bronchiectasis or chronic lung damage from fungal infections.
2. Reducing Pulmonary Exacerbations
One of the key benefits of brensocatib is its ability to reduce exacerbations, which are common in both ABPA and CPA. These flare-ups can lead to increased inflammation, infection, and lung tissue damage, further complicating the disease. The ASPEN trial (Phase 3 study) demonstrated that brensocatib significantly reduced the annualized rate of pulmonary exacerbations in patients with non-cystic fibrosis bronchiectasis. This benefit may extend to patients with aspergillosis, as frequent exacerbations can worsen lung function and overall health.
3. Slowing the Decline in Lung Function
Brensocatib also helps slow the decline in lung function, which is crucial for aspergillosis patients whose lung health may already be compromised by the infection. In chronic pulmonary aspergillosis (CPA), lung function decline can be progressive and irreversible without effective management. By reducing inflammation and exacerbations, brensocatib may help stabilize lung function and improve long-term outcomes for these patients.
4. Managing Chronic Inflammation in ABPA and CPA
Both ABPA and CPA are characterized by chronic inflammation in the airways. Brensocatib targets the underlying cause of much of this inflammation—neutrophil serine proteases—by inhibiting their activation. This could help reduce the chronic inflammation that causes damage to the airways and makes symptoms like cough, wheezing, and mucus production worse. For patients with aspergillosis and related respiratory complications, controlling this inflammation is key to managing symptoms and improving quality of life.
Clinical Evidence Supporting Brensocatib
The ASPEN trial, which included patients with bronchiectasis, demonstrated that brensocatib not only reduced exacerbations but also slowed the progression of lung function decline, as measured by forced expiratory volume in one second (FEV₁). Patients on brensocatib had a higher proportion of exacerbation-free days and better overall lung function than those on a placebo.
Although this trial did not focus solely on aspergillosis, its positive results suggest that brensocatib could be a valuable option for managing the lung damage and inflammation caused by Aspergillus infections, particularly in patients who have developed bronchiectasis as a result of the infection.
Safety and Side Effects
Like any medication, brensocatib can have side effects. The most common side effects observed in clinical trials included:
-
Hyperkeratosis (thickening of the skin)
-
Periodontal issues (such as gum inflammation)
-
Headache
-
Cough
-
Nasopharyngitis (inflammation of the nasal passages)
These side effects were generally mild to moderate. As brensocatib is still being evaluated for regulatory approval, ongoing monitoring and further clinical studies will help clarify its long-term safety profile.
Regulatory Status
Brensocatib has received FDA Priority Review for the treatment of non-cystic fibrosis bronchiectasis, and a decision is expected by August 12, 2025. If approved, it could become the first FDA-approved treatment for bronchiectasis and the first DPP-1 inhibitor for neutrophil-driven diseases. In the UK, Insmed, the manufacturer of brensocatib, has submitted a marketing authorization application to the MHRA. Pending approval, brensocatib could be available to patients in the UK by late 2025 or early 2026.
Conclusion
For aspergillosis patients, particularly those with bronchiectasis and chronic inflammation, brensocatib represents an exciting new treatment option. By targeting neutrophil-driven inflammation, reducing exacerbations, and slowing the decline in lung function, brensocatib offers hope for managing the long-term complications of Aspergillus infections. While it is still undergoing regulatory review, the clinical evidence supporting its efficacy suggests that it could become a valuable addition to the treatment arsenal for patients with aspergillosis.
Latest News posts
News archive